RELEASE: MolecuLight Successfully Completes SOC 2® Type I Audit and Accreditation

- Recent audit success demonstrates MolecuLight's commitment to data security.

RELEASE: MolecuLight Successfully Completes SOC 2® Type I Audit and Accreditation

- Recent audit success demonstrates MolecuLight's commitment to data security

TORONTO, April 19, 2023 /PRNewswire/ -- MolecuLight Inc., a leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, has announced its compliance with the SOC 2® Type standard I, after you have successfully completed your audit in accordance with the American Institute of Certified Public Accountants (AICPA) standards for Systems and Organizational Controls (SOC). This enables MolecuLight to better serve the needs of its customers around the world by ensuring that the company's data management practices and organizational controls meet the highest international standards.

MolecuLight's compliance with the SOC 2® standards validates that the company has implemented controls related to the security, availability and integrity of the treatment of the systems used to process user data, as well as the confidentiality and privacy of the information. "Achieving SOC 2 certification reinforces MolecuLight's ongoing commitment to the safety, availability and processing integrity of MolecuLight's point-of-care fluorescence imaging technologies," said Anil Amlani, CEO of MolecuLight. "Our certification demonstrates our commitment and business processes to maintain the highest level of security, privacy, availability and confidentiality for our customers."

As part of the process to achieve SOC 2® compliance, MolecuLight worked with PwC, an accredited auditor, to review the design and operational effectiveness of its MolecuLightDX® core imaging platform controls against applicable criteria. of trust services in terms of security, availability and confidentiality. These criteria included the imaging platform's operating software, how the devices handle customer and user data, and security policies and procedures. Over the course of the audit, MolecuLight demonstrated its ability to securely manage customer data and platform usage, as well as its security controls and processes.

MolecuLight i:X and DX are the only imaging devices for real-time detection of elevated bacterial load in wounds that are FDA and CE and Health Canada cleared. With clinical evidence including more than 75 peer-reviewed publications involving 1,600 patients, they are used by leading wound care centers globally.

About MolecuLight Inc.

MolecuLight Inc. is a privately held medical imaging company that has developed and markets its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight's suite of commercial devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and accessories, are portable point-of-care imaging devices for real-time detection and localization of bacterial load. in wounds and digital measurement of wounds. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway that includes two CPT® codes for physician work to perform "fluorescence imaging for presence, location, and load of bacteria" and facility payment for the Hospital Outpatient Department (HOPD) and the Ambulatory Surgical Center (ASC) through an Outpatient Payment Classification (APC) allocation. The company is also commercializing its unique fluorescence imaging platform technology to other global markets with relevant unmet needs in food safety, consumer cosmetics, and other key industrial markets.

If you want more information contact:

Rob SandlerResponsable de marketingMolecuLight Inc.T.


Download the images:

Photo -

View original content: